articles
MD Becker Partners publishes the Life Science Digest newsletter, which contains original articles on medical, financial, communications, marketing, and regulatory topics relevant to the biotechnology, pharmaceutical, and medical device industries. To view these articles, please visit the Life Science Digest newsletter site.
In view of the significant interest that we received from companies featured in our original articles, MD Becker Partners now offers customized reprints that can be tailored to a specific company, including special “call-outs” that highlight important company-specific information referenced in the text. Customized reprints can be uploaded to a company’s website or emailed to contacts for broader distribution. A sample article reprint is available by clicking here and reprint requests should be directed via email to: info@mdbpartners.com
We have also authored or contributed to other articles, journal publications, and abstracts. Note: access to full text versions may be available by clicking on the story dates below.
Newsletter articles
3/7/2010 - "For Biotechnology in 2010, it’s Déjà vu All over Again"
2/28/2010 - "Gut Check Time for GVHD Companies: BMT Tandem Meetings Review"
2/4/2010 - "Iron Safety Hits AMAG Pharmaceuticals"
1/14/2010 - "Biotech Deal Activity Declines…The Pause that Refreshes?"
1/4/2010 - "2009: Biotech’s Stealth Small Cap Rally"
12/9/2009 - "Graft Versus Host Disease: Failures and Future Opportunities"
12/7/2009 - "Buyout Buzz at ASH Hematology Confab"
Scientific publications
12/8/2008 - "Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy" in Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2987
7/1/2008 - "The use of chelated radionuclide (samarium-153-ethylene-diamine-tetra-methylene-phosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing" in Clin Cancer Res 2008 Jul 1;14(13):4241-9
9/12/2006 - "Development of optimal Lu-177 labeled monoclonal antibody (7E11) constructs (CYT-500) for radioimmunotherapy of hormone refractory prostate cancer" Abstract #B45 from the 2006 American Association for Cancer Research (AACR) annual meeting
Additional articles
9/18/2008 - "The Treatment of Palmar-plantar Erythrodysesthesia" By Michael D. Becker for MDNG
6/1/2008 - "Honing In on Chemoresistance Pathways" By Michael D. Becker for GEN (Genetic Engineering & Biotechnology News)
9/1/2007 - "Radiopharmaceuticals Need a Jump-STaRT" By Michael D. Becker for Oncology Business Review
11/6/2000 - "More Akin to Skin - Comparing and contrasting the independent efforts of Advanced Tissue Sciences and Organogenesis in the emerging field of tissue engineering" By Michael D. Becker for the Beck On Biotech newsletter